Lataa...
ABCG2 Overexpression Contributes to Pevonedistat Resistance
MLN4924 (pevonedistat) is a first-in-class NEDD8-activating enzyme (NAE) inhibitor in clinical trials for the treatment of solid tumors and hematologic malignancies. Despite the promising activity of MLN4924 observed in early trials, drug resistance has been noted in some patients. Identifying the u...
Tallennettuna:
| Julkaisussa: | Cancers (Basel) |
|---|---|
| Päätekijät: | , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7072604/ https://ncbi.nlm.nih.gov/pubmed/32059437 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12020429 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|